论文部分内容阅读
目的对比阿卡波糖或阿格列汀联合甘精胰岛素治疗2型糖尿病的临床疗效。方法 86例2型糖尿病患者随机分为阿卡波糖组和阿格列汀组,每组43例。阿卡波糖组给予阿卡波糖+甘精胰岛素治疗,阿格列汀组给予阿格列汀+甘精胰岛素治疗,比较两组临床疗效。结果与治疗前比较,治疗后两组患者空腹血糖(FPG)、餐后2 h血糖(2 h PBG)、糖化血红蛋白(HbA1c)、稳态胰岛素评价指数(HOMA-IR)及体质量指数(BMI)均显著下降(P<0.05),胰岛β细胞指数(HOMA-β)显著升高(P<0.05);与阿卡波糖组比较,阿格列汀组患者HbA1c(6.35±0.92)%、HOMA-IR(1.69±0.48)及BMI(21.10±3.82)kg/m~2下降,HOMA-β(64.55±10.21)升高更为明显(P<0.05)。结论阿卡波糖或阿格列汀与甘精胰岛素联用均可有效控制糖尿病患者血糖,但阿格列汀与甘精胰岛素联用后患者体重指数降低更为明显,值得临床推广使用。
Objective To compare the clinical efficacy of acarbose or alogliptin with insulin glargine in the treatment of type 2 diabetes mellitus. Methods 86 cases of type 2 diabetes were randomly divided into acarbose group and alogliptin group, 43 cases in each group. Acarbose group given acarbose + insulin glargine, the alogliptin group were treated with alogliptin + insulin glargine, the clinical efficacy of the two groups were compared. Results Compared with those before treatment, fasting plasma glucose (FPG), postprandial 2h PBG, HbA1c, HOMA-IR and BMI (P <0.05), HOMA-β was significantly increased (P <0.05). Compared with acarbose group, HbA1c (6.35 ± 0.92)%, The levels of HOMA-IR (1.69 ± 0.48) and BMI (21.10 ± 3.82) kg / m 2 decreased, while HOMA-β (64.55 ± 10.21) increased more significantly (P <0.05). Conclusions Both acarbose and alogliptin combined with insulin glargine can effectively control the blood sugar of diabetic patients. However, the combination of alogliptin and insulin glargine reduces the body mass index more obviously and is worthy of clinical application.